Eli Lilly's Growth Outlook Strengthens on Obesity Drug Pipeline and Market Expansion

Key Facts

1Eli Lilly is rated as a strong buy with a $1,623 price target.

2The Q2 launch of Orforglipron is expected to expand the company's market share.

3Expansion of Medicare and Medicaid eligibility will drive weight-loss drug sales.

4Anticipated 2027 approval for Retatrutide targets the most severe obesity cases.

Eli Lilly (LLY) has received a "strong buy" rating from analysts, with a price target set at $1,623 per share. The company's growth trajectory is supported by the anticipated Q2 launch of Orforglipron, which is expected to capture a larger share of the obesity drug market. Furthermore, the expansion of Medicare and Medicaid eligibility for weight-loss treatments is projected to significantly drive sales volumes. Looking ahead, the potential 2027 approval of Retatrutide offers a long-term catalyst for treating severe obesity cases. These developments reinforce Eli Lilly's leadership in the pharmaceutical sector and suggest continued upward momentum for its stock. Analysts believe these product catalysts and insurance expansions will maintain the company's competitive edge in the healthcare industry.